Interstitial lung diseases (ILDs) are heterogeneous disorders, involving a large number of
conditions, the approach to which continues to pose an enormous challenge for …

Introduction The enthusiasm generated by the approval of pirfenidone and nintedanib as the
first effective therapies for IPF led the IPF scientific community to investigate an increasing …

Interstitial lung diseases (ILDs) are inflammatory diseases characterized by slow and
progressive destruction of alveolar-capillary functional units, often leading to respiratory …

In 1911, one of the most emblematic figures in poetry, Constantine Kavafis, published a
poem named “Ithaka” which symbolizes the ultimate destination of a long journey. Kavafis …

Fibrotic interstitial lung diseases (ILDs) are often challenging to diagnose and classify, but
an accurate diagnosis has significant implications for both treatment and prognosis. A …

Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and
Clinical Insights - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Interstitial lung disease (ILD) has a high prevalence among patients with systemic sclerosis
(SSc), carrying high mortality and morbidity. During the last decade, the emergence of new …

The chronic fibrosing idiopathic interstitial pneumonias (IIPs) are a group of heterogeneous
pulmonary parenchymal disorders described by radiologic and histological patterns termed …

Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5‐year survival of
approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly …

Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …